- Category: Innovative care
- Published: Wednesday, 09 April 2014 10:16
The majority of genetic diseases are complex conditions that call for both the development of new diagnostic tools and the discovery of new treatment options. To care for children with these diseases, Imagine aims to establish close links between applied and clinical research to accelerate new discoveries.
The Institute's clinical research into genetic diseases concerns the various integrated care pathways included in the IHU's research and healthcare program.
At Imagine, our aim for clinical research is two-fold :
- Increase the number of innovative therapeutic studies and transform knowledge into effective treatments as rapidly as possible, through drug therapies, biotherapies, cell therapies and gene therapies.
- Increase the number of patients taking part in these trials.
In order to develop close links between applied research and clinical practice, Imagine decided to provide additional resources and formed a dedicated team. A Clinical Research Manager was recruited in September 2012 to assess needs and set about organizing interaction with the hospital's clinical research structures, the Clinical Research Unit, the Clinical Investigation Center and the Finance and Research Department’s Research and Innovation team. The other addition to the team recruited in September 2012 is a regulatory affairs pharmacist, hired in response to the growing demand for gene and cell therapy trials.
Imagine will back the clinical departments and existing research teams by introducing additional measures
- Reinforced human resources for the CIC (Clinical Investigation Center), late in 2013 or early in 2014,
- A team of mobile clinical research nurses, starting in September 2013. The team will be trained to care for patients included in clinical trials in the hospital
- First clinical research coordinator recruited at the end of 2013 to anchor a sustainable clinical research organization in certain departments and/or reference centers.
Imagine may also develop its own clinical trials during 2014, building on a more closely coordinated promotion structure.